TY - JOUR
T1 - Inferior vena cava filters
AU - Weinberg, Ido
AU - Kaufman, John
AU - Jaff, Michael R.
N1 - Funding Information:
Dr. Kaufman has received research funding from the National Institutes of Health , W. L. Gore, and Guerbet; consulting fees from Biotronik, EV3, Guerbet, Cook, and W. L. Gore; owns stock in Veniti and Hatch Medical; and has served on the medical advisory boards of VuMedi and Bio2 Medical. Dr. Jaff is a noncompensated advisor to Abbott Vascular, Cordis Corporation, Covidien Vascular, and Medtronic Vascular; a member of the data safety and monitoring board for EKOS Corporation; and a board member of VIVA Physicians, a 501(c) 3 not-for-profit education and research organization. Dr. Weinberg has reported that he has no relationships relevant to the contents of this paper to disclose.
PY - 2013/6
Y1 - 2013/6
N2 - Venous thromboembolism is common. Most pulmonary emboli arise as thromboses in the deep veins of the lower extremities and may result in serious complications. Inferior vena cava filters (IVCF) are intended to prevent the passage of deep vein thrombosis to the pulmonary arteries. Accepted indications for IVCF placement include the presence of acute venous thromboembolism with inability to administer anticoagulation medication or failure of anticoagulation. Despite these clear indications, IVCF have been commonly placed in patients for primary prevention of pulmonary emboli in patients deemed to be at high risk, along with several other "soft" indications. As a result, IVCF use has been rising over the past 2 decades, especially given the retrievable nature of modern devices. Nonetheless, IVCF are not free of complications, which may occur during implantation and retrieval and while retained in the body. Despite this increase in use, the long-term efficacy remains unclear, and the management of patients with retained filters is often controversial. Finally, filter retrieval in eligible patients is relatively infrequent, suggesting that systems must be in place to improve appropriate filter use and to increase retrieval.
AB - Venous thromboembolism is common. Most pulmonary emboli arise as thromboses in the deep veins of the lower extremities and may result in serious complications. Inferior vena cava filters (IVCF) are intended to prevent the passage of deep vein thrombosis to the pulmonary arteries. Accepted indications for IVCF placement include the presence of acute venous thromboembolism with inability to administer anticoagulation medication or failure of anticoagulation. Despite these clear indications, IVCF have been commonly placed in patients for primary prevention of pulmonary emboli in patients deemed to be at high risk, along with several other "soft" indications. As a result, IVCF use has been rising over the past 2 decades, especially given the retrievable nature of modern devices. Nonetheless, IVCF are not free of complications, which may occur during implantation and retrieval and while retained in the body. Despite this increase in use, the long-term efficacy remains unclear, and the management of patients with retained filters is often controversial. Finally, filter retrieval in eligible patients is relatively infrequent, suggesting that systems must be in place to improve appropriate filter use and to increase retrieval.
KW - deep vein thrombosis
KW - inferior vena cava filter
KW - pulmonary embolism
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84879336701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879336701&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2013.03.006
DO - 10.1016/j.jcin.2013.03.006
M3 - Review article
C2 - 23787230
AN - SCOPUS:84879336701
SN - 1936-8798
VL - 6
SP - 539
EP - 547
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 6
ER -